Inventor · disambiguated record
Steven C. Almo
Also filed as: ALMO STEVEN · ALMO STEVEN C · ALMO STEVEN CRAIG
14 granted patents·19 pending applications·26 citations·filing 2011–2025
87Inventor score
Files withALBERT EINSTEIN COLLEGE MEDICINE24ALBERT EINSTEIN COLLEGE MEDICINE INC4ALBERT EINSTEIN COLLEGE MEDICINE YESHIVA UNIV2ALMO STEVEN C1EINSTEIN COLL MED1
Top patents by PatentIndex Score
33 records- 0188US9688991B2Aptamer-targetted antigen deliveryALBERT EINSTEIN COLLEGE MEDICINE YESHIVA UNIV·Filed 2013·Granted Jun 27, 2017·18 cites·13 claims
- 0282US11339201B2Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereofALBERT EINSTEIN COLLEGE MEDICINE·Filed 2017·Granted May 24, 2022·3 cites·18 claims
- 0377US11226339B2Methods for high throughput receptor:ligand identificationALBERT EINSTEIN COLLEGE MEDICINE·Filed 2018·Granted Jan 18, 2022·1 cites·7 claims
- 0476US2024270812A1Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapiesALBERT EINSTEIN COLLEGE MEDICINE·Filed 2024·Application pending·0 cites
- 0572US11279728B2Broad spectrum viral inhibitorALBERT EINSTEIN COLLEGE MEDICINE·Filed 2018·Granted Mar 22, 2022·3 cites·19 claims
- 0669US2021047384A1Syntac polypeptides and uses thereofALBERT EINSTEIN COLLEGE MEDICINE·Filed 2020·Application pending·0 cites
- 0768US11905322B2Engineered PD-1 variantsALBERT EINSTEIN COLLEGE MEDICINE·Filed 2021·Granted Feb 20, 2024·0 cites·19 claims
- 0867US10048271B2Methods for high throughput receptor:ligand identificationALBERT EINSTEIN COLLEGE MEDICINE YESHIVA UNIV·Filed 2013·Granted Aug 14, 2018·1 cites·17 claims
- 0967US2021238254A1Syntac polypeptides and uses thereofALBERT EINSTEIN COLLEGE MEDICINE·Filed 2020·Application pending·0 cites
- 1067US2020377569A1Syntac polypeptides and uses thereofALBERT EINSTEIN COLLEGE MEDICINE·Filed 2020·Application pending·0 cites
- 1163US10882893B2TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapiesALBERT EINSTEIN COLLEGE MEDICINE·Filed 2019·Granted Jan 5, 2021·0 cites·6 claims
- 1263US2023052675A1Cellular platform for rapid and comprehensive t-cell immunomonitoringALBERT EINSTEIN COLLEGE MEDICINE·Filed 2022·Application pending·0 cites
- 1362US2021388052A1Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapiesALBERT EINSTEIN COLLEGE MEDICINE·Filed 2021·Application pending·0 cites
- 1461US2025025473A1Cell impermeable kinase inhibitors to treat sars-cov-2 and/or hsv viral infectionsALBERT EINSTEIN COLLEGE MEDICINE·Filed 2022·Application pending·0 cites
- 1559US2018282392A1Syntac polypeptides and uses thereofALBERT EINSTEIN COLLEGE MEDICINE INC·Filed 2018·Application pending·0 cites
- 1658US12258304B2Compounds and methods for treatment of bacterial infectionsALBERT EINSTEIN COLLEGE MEDICINE·Filed 2020·Granted Mar 25, 2025·0 cites·20 claims
- 1758US11352413B2Engineered PD-1 variantsALBERT EINSTEIN COLLEGE MEDICINE·Filed 2017·Granted Jun 7, 2022·0 cites·27 claims
- 1857US2025197344A1Compounds and methods for treatment of bacterial infectionsALBERT EINSTEIN COLLEGE MEDICINE·Filed 2025·Application pending·0 cites
- 1955US2024201167A1The immunomodulatory ligand b7-1 mediates synaptic remodeling by p75ntrALBERT EINSTEIN COLLEGE MEDICINE·Filed 2022·Application pending·0 cites
- 2053US2024287123A1Antiviral nucleoside analoguesVICTORIA LINK LTD·Filed 2022·Application pending·0 cites
- 2152US10280208B2TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapiesALBERT EINSTEIN COLLEGE MEDICINE INC·Filed 2015·Granted May 7, 2019·0 cites·14 claims
- 2252US2023364234A1Compositions and methods for chimeric antigen receptor (car)-modified cell modulationALBERT EINSTEIN COLLEGE MEDICINE·Filed 2021·Application pending·0 cites
- 2352US2023126784A1A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activityALBERT EINSTEIN COLLEGE MEDICINE·Filed 2021·Application pending·0 cites
- 2451US2017058015A1Syntac polypeptides and uses thereofALBERT EINSTEIN COLLEGE MEDICINE INC·Filed 2015·Application pending·0 cites
- 2550US12390541B2Mutant variants of PD-1 receptor with selective binding to PD-L1 and uses thereofALBERT EINSTEIN COLLEGE MEDICINE·Filed 2019·Granted Aug 19, 2025·0 cites·12 claims
- 2649US2017176435A1Cellular platform for rapid and comprehensive t-cell immunomonitoringALBERT EINSTEIN COLLEGE MEDICINE INC·Filed 2015·Application pending·0 cites
- 2749US2022348974A1Biotin synthases for efficient production of biotinALBERT EINSTEIN COLLEGE MEDICINE·Filed 2020·Application pending·0 cites
- 2847US11382919B2Prevention and treatment of viral infectionsALBERT EINSTEIN COLLEGE MEDICINE·Filed 2018·Granted Jul 12, 2022·0 cites·18 claims
- 2946US2015368316A1A selective high-affinity immune stimulatory reagent and uses thereofEINSTEIN COLL MED·Filed 2014·Application pending·0 cites
- 3044US2022227886A1Antibody-based method to identify, purify, and manipulate cell types and processesALBERT EINSTEIN COLLEGE MEDICINE·Filed 2020·Application pending·0 cites
- 3142US2012078530A1Method for determining receptor-ligand pairsALMO STEVEN C·Filed 2011·Application pending·0 cites
- 3241US11407806B2Precision activation of HIV-specific CTLS to eliminate reactivated latent T cellsALBERT EINSTEIN COLLEGE MEDICINE·Filed 2018·Granted Aug 9, 2022·0 cites·24 claims
- 3340US10717776B2Tumor necrosis factor 1B (TNF-1B) mutants and methods of use thereof to screen for candidate therapeutic compoundsALBERT EINSTEIN COLLEGE MEDICINE·Filed 2018·Granted Jul 21, 2020·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Steven C. Almo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →